Correlation of vascular endothelial growth factor with survival and pathological characteristics of patients with osteosarcoma: A systematic review and meta-analysis
- PMID: 35707976
- DOI: 10.1111/ecc.13629
Correlation of vascular endothelial growth factor with survival and pathological characteristics of patients with osteosarcoma: A systematic review and meta-analysis
Abstract
Objective: This study aimed to assess the prognostic role of vascular endothelial growth factor (VEGF) expression in osteosarcoma.
Methods: Systematic searches of PubMed, Embase, CINAHL, Cochrane Library, ScienceDirect, and Web of Science were conducted. The correlation between VEGF expression and patients' survival was our primary endpoint. The secondary endpoints were the associations between VEGF level and patients' sociodemographic and pathological characteristics. The pooled hazard ratio (HR) or odd ratio (OR) and corresponding 95% confidence intervals (CIs) were obtained to assess the associations between VEGF expression and the target factors. Subgroup and meta-regression analyses were conducted to explore potential factors that associated with VEGF efficacy.
Results: The combined HR suggested that a positive VEGF status has a negative impact on overall survival (OS) (HR = 2.58; 95% CI, 2.09-3.19; P < 0.0001) and disease-free survival (DFS) (HR = 2.54; 95% CI, 1.84-3.50; P < 0.0001) in patients with osteosarcoma. Meta-regression analysis ruled out the influence of cut-off value, disease stage, histological subtype, disease grade, tumour location, geographic area, publication year, and method of HR acquisition on heterogeneity. Results showed that VEGF expression was closely correlated with tumour staging, chemotherapy response, and metastasis.
Conclusion: Based on the study results, VEGF could serve as an effective biomarker of prognosis in patients with osteosarcoma. Besides, VEGF was related to increased tumour malignancy, which might help guide clinical decision-making regarding therapy and outcomes.
Keywords: osteosarcoma; pathological characteristics; prognosis; survival; vascular endothelial growth factor.
© 2022 John Wiley & Sons Ltd.
Similar articles
-
Effects of vascular endothelial growth factor expression on pathological characteristics and prognosis of osteosarcoma.Clin Exp Med. 2016 Nov;16(4):577-584. doi: 10.1007/s10238-015-0382-1. Epub 2015 Aug 29. Clin Exp Med. 2016. PMID: 26319790
-
Prognostic significance of VEGF expression in osteosarcoma: a meta-analysis.Tumour Biol. 2014 Jan;35(1):155-60. doi: 10.1007/s13277-013-1019-1. Epub 2013 Aug 2. Tumour Biol. 2014. PMID: 23907576
-
Impact of vascular endothelial growth factor expression on overall survival in patients with osteosarcoma: a meta-analysis.Tumour Biol. 2014 Mar;35(3):1745-9. doi: 10.1007/s13277-014-1692-8. Epub 2014 Feb 11. Tumour Biol. 2014. PMID: 24515658
-
Prognostic value of vascular endothelial growth factor expression in women with ovarian cancer: A meta-analysis.J BUON. 2015 May-Jun;20(3):870-8. J BUON. 2015. PMID: 26214642 Review.
-
The relationship between the expression of Ki-67 and the prognosis of osteosarcoma.BMC Cancer. 2021 Mar 1;21(1):210. doi: 10.1186/s12885-021-07880-y. BMC Cancer. 2021. PMID: 33648449 Free PMC article.
Cited by
-
VEGFC Gene Expression Is Associated with Tumor Progression and Disease-Free Survival in Cutaneous Squamous Cell Carcinoma.Int J Mol Sci. 2023 Dec 27;25(1):379. doi: 10.3390/ijms25010379. Int J Mol Sci. 2023. PMID: 38203550 Free PMC article.
-
Immunostaining for VEGF and Decorin Predicts Poor Survival and Recurrence in Canine Soft Tissue Sarcoma.Vet Sci. 2023 Mar 28;10(4):256. doi: 10.3390/vetsci10040256. Vet Sci. 2023. PMID: 37104411 Free PMC article.
References
REFERENCES
-
- Adams, J., Carder, P. J., Downey, S., Forbes, M. A., MacLennan, K., Allgar, V., Kaufman, S., Hallam, S., Bicknell, R., Walker, J. J., Cairnduff, F., Selby, P. J., Perren, T. J., Lansdown, M., & Banks, R. E. (2000). Vascular endothelial growth factor (VEGF) in breast cancer: Comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Research, 60(11), 2898-2905.
-
- Bajpai, J., Chandrasekharan, A., Simha, V., Talreja, V., Karpe, A., Pandey, N., Singh, A., Rekhi, B., Vora, T., Ghosh, J., Banavali, S., & Gupta, S. (2018). Outcomes in treatment-naïve patients with metastatic extremity osteosarcoma treated with OGS-12, a novel non-high-dose methotrexate-based, dose-dense combination chemotherapy, in a tertiary care cancer center. Journal of Global Oncology, 4, 1-10. https://doi.org/10.1200/JGO.17.00137
-
- Bajpai, J., Sharma, M., Sreenivas, V., Kumar, R., Gamnagatti, S., Khan, S. A., Rastogi, S., Malhotra, A., & Bakhshi, S. (2009). VEGF expression as a prognostic marker in osteosarcoma. Pediatric Blood & Cancer, 53(6), 1035-1039. https://doi.org/10.1002/pbc.22178
-
- Baptista, A. M., Camargo, A. F. D. F., Filippi, R. Z., Oliveira, C. R. G. C. M. D., Azevedo Neto, R. S. D., & Camargo, O. P. D. (2014). Correlation between the expression of vegf and survival in osteosarcoma. Acta Ortopedica Brasileira, 22(5), 250-255. https://doi.org/10.1590/1413-78522014220500978
-
- Becker, R. G., Galia, C. R., Morini, S., & Viana, C. R. (2013). Immunohistochemical expression of vegf and her-2 proteins in osteosarcoma biopsies. Acta Ortopedica Brasileira, 21(4), 233-238. https://doi.org/10.1590/S1413-78522013000400010
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical